Human Anti-IL15 Recombinant Antibody (clone DISC0280) (CAT#: PABZ-081)

Figure 1 Inhibition of hIL‐15‐dependent cell effects in CTLL‐2, KIT225 and M‐07e cells by anti‐IL‐15 mAbs or CAT002, a human IgG1 isotype control

(A) IL‐15 dependent KIT225 cell survival assay, (B) IL‐15 dependent CTLL‐2 cell survival assay, (C) IL‐15 dependent M‐07e cell survival assay. All data is the mean of three experiments and error bars represent standard deviation. hIL‐15, human IL‐15; hIL‐15/sIL‐15Rα, pre‐associated complex of human IL‐15 and soluble IL‐15 receptor α; IL‐15, interleukin‐15.

Finch, D. K., Midha, A., Buchanan, C. L., Cochrane, D., Craggs, R. I., Cruwys, S., ... & Pattison, D. V. (2011). Identification of a potent anti‐IL‐15 antibody with opposing mechanisms of action in vitro and in vivo. British journal of pharmacology, 162(2), 480-490.

Figure 2 Inhibitory effects of DISC0280 on human interleukin‐15 (hIL‐15) binding to interleukin 15 receptor α (IL‐15Rα).

Labelled hIL‐15 at a single concentration was incubated with immobilized IL‐15Rα‐Fc in the presence of a titration of inhibitor, as described. All data is the mean of three experiments and error bars represent standard deviation.

Finch, D. K., Midha, A., Buchanan, C. L., Cochrane, D., Craggs, R. I., Cruwys, S., ... & Pattison, D. V. (2011). Identification of a potent anti‐IL‐15 antibody with opposing mechanisms of action in vitro and in vivo. British journal of pharmacology, 162(2), 480-490.

Figure 3 Administration of DISC0280 and hIL‐15 increases IL‐5 levels.

The plasma concentrations of IL‐5 in the terminal bleeds of all the mice treated as in Figure 6, were measured. Limit of Quantification (LOQ) is shown at 3 pg·mL⁻¹. Error bars show standard deviation from the mean. *P < 0.05, **P < 0.01, ***P < 0.001. hIL‐15, human interleukin‐15; hIL‐15Rα, human interleukin 15 receptor α; IL‐5, interleukin‐5.

Finch, D. K., Midha, A., Buchanan, C. L., Cochrane, D., Craggs, R. I., Cruwys, S., ... & Pattison, D. V. (2011). Identification of a potent anti‐IL‐15 antibody with opposing mechanisms of action in vitro and in vivo. British journal of pharmacology, 162(2), 480-490.